Drug General Information
Drug ID
D0W1SL
Former ID
DNC009127
Drug Name
BUTYLATEDHYDROXYTOLUENE
Drug Type
Small molecular drug
Indication Discovery agent Phase 1 [524883]
Structure
Download
2D MOL

3D MOL

Formula
C15H24O
Canonical SMILES
CC1=CC(=C(C(=C1)C(C)(C)C)O)C(C)(C)C
InChI
1S/C15H24O/c1-10-8-11(14(2,3)4)13(16)12(9-10)15(5,6)7/h8-9,16H,1-7H3
InChIKey
NLZUEZXRPGMBCV-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) Carbonic anhydrase II Target Info Inhibitor [529973]
KEGG Pathway Nitrogen metabolism
Proximal tubule bicarbonate reclamation
Collecting duct acid secretion
Gastric acid secretion
Pancreatic secretion
Bile secretion
NetPath Pathway IL4 Signaling Pathway
EGFR1 Signaling Pathway
Reactome Erythrocytes take up carbon dioxide and release oxygen
Erythrocytes take up oxygen and release carbon dioxide
Reversible hydration of carbon dioxide
WikiPathways Reversible Hydration of Carbon Dioxide
Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes
Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes
References
Ref 524883ClinicalTrials.gov (NCT02221375) Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat Soft MistTM Inhaler B in Healthy Male Volunteers. U.S. National Institutes of Health.
Ref 529973Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. Epub 2009 Feb 4.Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.